Seidel D
Institut for Clinical Chemistry, University of Munich, Klinikum Grosshadern.
Ther Umsch. 1990 Jun;47(6):514-9.
The HELP procedure provides a new means of very efficiently treating high LDL concentrations in severe hypercholesterolemia with the additional effect of lowering Lp(a) and fibrinogen while HDL are increased during long-term treatment. The HELP treatment also significantly improves plasma viscosity, erythrocyte aggregation and erythrocyte filtration. Overall treatment tolerance is very good, and no major complications have been observed after approximately 10,000 single treatments in 155 patients--some of them treated for more than three years. In combination with HMG-CoA reductase inhibitors, a mean interval value of--75% for LDL as compared to the starting concentration may be achieved. The treatment has the advantage that the patient is not exposed to foreign proteins or compounds with attendant immunological problems. It displays a high degree of reproducibility and an almost unlimited capacity, guaranteeing a constant therapy independent of the clinic performing the treatment. We trust that the clinical benefit of this treatment regimen will be substantial for those patients who have problems in clearing LDL from their plasma pool and who are at the same time sensitive to elevated LDL levels by the development of premature coronary sclerosis.
HELP 程序提供了一种非常有效的新方法,用于治疗严重高胆固醇血症中的高 LDL 浓度,同时具有降低 Lp(a) 和纤维蛋白原的额外效果,并且在长期治疗期间 HDL 会升高。HELP 治疗还能显著改善血浆粘度、红细胞聚集和红细胞过滤。总体治疗耐受性非常好,在 155 名患者中进行了约 10000 次单次治疗后,未观察到重大并发症——其中一些患者接受治疗超过三年。与 HMG-CoA 还原酶抑制剂联合使用时,与起始浓度相比,LDL 的平均间隔值可达到 -75%。该治疗的优点是患者不会接触到伴有免疫问题的外来蛋白质或化合物。它具有高度的可重复性和几乎无限的容量,保证了独立于进行治疗的诊所的持续治疗。我们相信,对于那些血浆池中 LDL 清除存在问题且同时因过早发生冠状动脉硬化而对升高的 LDL 水平敏感的患者,这种治疗方案将带来实质性的临床益处。